Blog Category

Press Releases

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024

,

/

25 June 2024

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

,

/

12 June 2024

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity

,

/

10 June 2024

Combined General Meeting of June 24, 2024

,

/

7 June 2024

Biophytis announces the design of its phase 2 OBA clinical study in obesity

,

/

14 May 2024

Biophytis is deploying its partnership strategy in obesity

, ,

/

29 April 2024

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

,

/

19 April 2024

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity

,

/

18 April 2024

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

,

/

8 April 2024

Biophytis announces its 2023 financial results and provides an update on its business activities

,

/

8 April 2024

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024

,

/

4 April 2024

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

,

/

22 March 2024